

Published in final edited form as:

*Curr Opin Allergy Clin Immunol.* 2012 December ; 12(6): 616–622. doi:10.1097/ACI.0b013e328358cc0b.

## Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis

Anne Puel<sup>1</sup>, Sophie Cypowyj<sup>2</sup>, László Maródi<sup>3</sup>, Laurent Abel<sup>1,2</sup>, Capucine Picard<sup>1,4</sup>, and Jean-Laurent Casanova<sup>1,2</sup>

<sup>1</sup>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Inserm U980 and University Paris Descartes, Necker Medical School, Paris Sorbonne Cité, Paris, France, EU

<sup>2</sup>Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA

<sup>3</sup>Department of Infectious and Paediatric Immunology, University of Debrecen Medical and Health Science Centre, Debrecen, Hungary, EU

<sup>4</sup>Study Centre for Primary Immunodeficiencies, Assistance Publique Hôpitaux de Paris, Necker Hospital, Paris, France, EU

### Abstract

**Purpose of review**—Chronic mucocutaneous candidiasis (CMC) is characterised by recurrent or persistent symptomatic infection of the nails, skin and mucosae mostly by *Candida albicans*. CMC is common in patients with profound primary T-cell immunodeficiency, who often display multiple infectious and autoimmune diseases. Patients with syndromic CMC, including autosomal dominant (AD) hyper IgE syndrome (HIES) and autosomal recessive (AR) autoimmune polyendocrinopathy syndrome type I (APS-I), display fewer other infections. Patients with isolated CMC (CMCD) rarely display any other severe disease. We review here recent progress in the genetic dissection of these three types of inherited CMC.

**Recent findings**—Low IL-17 T cell proportions were reported in patients with AD-HIES bearing heterozygous *STAT3* mutations, prone to CMC and staphylococcal diseases, and in a kindred with AR *CARD9* deficiency, prone to CMC and other fungal infections. High levels of neutralising autoantibodies against IL-17 cytokines were documented in patients with APS-I presenting with CMC as their only infectious disease. The first three genetic aetiologies of CMCD were then reported: AR IL-17RA and AD IL-17F deficiencies and AD *STAT1* gain-of-function, impairing IL-17-producing T cell development.

**Summary**—Inborn errors of human IL-17 immunity underlie CMC. Impaired IL-17 immunity may therefore account for CMC in other settings, including patients with acquired immunodeficiency.

### Keywords

Primary immunodeficiencies; chronic mucocutaneous candidiasis; interleukin-17 immunity; *Candida albicans*

---

Author of correspondence: Anne, Puel, Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Inserm U980 and University Paris Descartes, Necker Medical School, Paris Sorbonne Cité, 156 rue de Vaugirard, 75015 Paris, France, EU, 33 1 40 61 53 87, anne.puel@inserm.fr.

The authors declare no conflict of interest.

## Introduction

Chronic mucocutaneous candidiasis (CMC) is characterised by recurrent or persistent symptomatic mucocutaneous infections caused by fungi of the genus *Candida*, mostly the commensal *Candida albicans*, affecting the nails, skin, and oral and genital mucosae (1–5). CMC is frequent in newborns and children (6) and is also common in patients with broad and profound quantitative or qualitative, acquired or inherited T-cell deficiencies, in whom it manifests principally as severe recurrent oral candidiasis (7–10). Severe oropharyngeal candidiasis remains common in HIV-infected patients and was the most frequent opportunistic fungal infection in these patients before the introduction of effective antiretroviral treatments (7, 11). It is also seen in patients on immunosuppressive, antibiotic or steroid treatments (1). Patients with primary immunodeficiencies (PIDs) affecting T cells, including severe combined immunodeficiency (SCID) (12) and combined immunodeficiencies (CIDs) (12, 13), are also prone to CMC. However, in these PIDs, CMC is only one of many infections to which patients are susceptible and there may also be other clinical signs, such as autoimmunity. By contrast, CMC is the principal or only infectious disease frequently observed in patients with autosomal dominant hyper IgE syndrome (AD-HIES), who also display severe skin and pulmonary staphylococcal disease, bearing dominant negative mutations of the *STAT3* transcription factor gene (14), and in patients with autosomal recessive autoimmune polyendocrinopathy syndrome type I (AR APS-I) due to *AIRE* mutations, who are not susceptible to any other infectious disease (3). Finally, CMC has been reported together with dermatophytosis and *Candida* meningitis in the only family with *CARD9* deficiency identified to date (15). We will refer to these three conditions as “syndromic CMC” below.

Some patients with CMC have no other prominent, overt clinical manifestations (1, 2, 4). This rare condition (about 1/100,000 individuals) is often referred to as CMC disease (CMCD) (OMIM 114580, 607644, 212050, 613953, 613956). The first sporadic cases were described in the 1960s and the first familial cases, typically with segregation as an AD trait or, more rarely, as an AR trait in some consanguineous families, were reported in the 1970s (16–19). Over the next 40 years, other sporadic and familial cases were reported (15, 20–60), suggesting that CMCD results from single-gene lesions in at least some patients. Invasive candidiasis (15, 34), dermatophytosis (25, 26), bacterial infections of the respiratory tract and staphylococcal diseases of the skin (32, 33, 61) have been reported in a few patients. In addition, some patients with CMCD display thyroid autoimmunity (2, 22, 27, 35, 38, 45, 54, 56–58). Finally, CMCD is generally debilitating, but may also be life-threatening, due to the associated risks of oral or oesophageal squamous cell carcinoma (20, 30, 50, 54, 56) and cerebral aneurysm (31, 36, 37, 49, 56). However, no robust immunological phenotype has emerged from the many studies carried out, despite the large number of patients with CMCD reported (1, 2, 21, 28, 29, 33, 39, 41, 44, 51, 53, 62–69). Various immunological treatments were proposed in the 1970s (18, 22, 70–74) but, from the 1980s onwards, with the advent of antifungal agents, research into CMCD declined, probably accounting for the paradoxical lack of published reports on the clinical features of patients with CMCD. We review here recent progress in the genetic dissection of the primary T-cell deficiencies underlying CMC, syndromic CMC, and CMCD.

### 1. CMC associated with primary T-cell immunodeficiencies

Patients with SCID lack autologous T cells and are highly vulnerable to a broad range of microorganisms, including *C. albicans* in particular. Indeed, severe oropharyngeal candidiasis is common in these patients (8–10, 12, 63). Patients with CIDs and impaired T-cell development and/or function are also often prone to CMC, although they generally also develop other often more severe infectious diseases (12). CMC has been reported in patients with AR CD25 deficiency, who have low T-cell counts and are highly susceptible to viral

and bacterial diseases, persistent oral thrush and *Candida* esophagitis (75, 76). It has also been found in patients with X-linked recessive (XR) NEMO disorders or autosomal dominant (AD)  $\text{I}\kappa\text{B}\alpha$  disorders, both of which result in a complex PID conferring susceptibility to invasive encapsulated pyogenic bacterial and environmental mycobacterial infections, in particular (77). CMC has also been reported in patients with AR DOCK8 deficiency, a severe CID associated with recurrent viral and bacterial infections (78, 79), impaired T-cell activation and low IL-17-producing T-cell counts (80, 81) and in patients with AR TYK2 deficiency, which is associated with susceptibility to viral, intracellular and extracellular bacterial diseases (82). Patients with AR TCR- $\alpha$  deficiency, which is associated with susceptibility to viral and bacterial diseases, have also been reported to display CMC (83), and CMC has also been described in patients with AR ORAI1 deficiency, which is associated with severe viral, bacterial, mycobacterial and fungal infections (84), in patients with AR MST1 deficiency, which is associated with recurrent bacterial and viral infections (85) (Crequer A., manuscript in preparation) and in patients with AR IRF8 deficiency, most of whom present severe mycobacterial disease (86). Finally, CMC has been documented in more complex T-cell disorders (13). By contrast, PIDs not affecting T-cell number and/or function, such as those affecting mostly B cells, phagocytes or complement, are not usually associated with CMC (13, 87). These findings demonstrate the essential role of human T cells in mucocutaneous immunity to *C. albicans*.

## 2. Syndromic CMC

CMC is one of the two main infectious diseases affecting patients with AD-HIES, bearing mutations in *STAT3*, the other being recurrent staphylococcal disease of the skin and lungs (14, 88). These patients have very small proportions of IL-17- and IL-22-secreting T cells, probably due to impaired STAT3-dependent signalling downstream from IL-6, IL-21 and/or IL-23 (Figure 1) (89–93), which have been shown to be essential for the differentiation or maintenance of Th17 cells in mice (94). An albeit smaller decrease in the proportion of IL-17 T cells was also observed in patients with AR IL-12p40 or IL-12R $\beta$ 1 deficiency, who suffer from Mendelian susceptibility to mycobacterial disease (MSMD) and, to a lesser extent, mild CMC, probably due to impaired IL-23 signalling (91, 95, 96) (Rodríguez-Gallego C., manuscript in preparation). A small proportion of IL-17-producing T cells was also found in the only kindred with AR CARD9 deficiency reported to date, some of the members of which presented CMC, superficial skin dermatophytosis and invasive candidiasis (meningitis) (15). As only one CARD9-deficient kindred has been reported, it would be premature to draw firm conclusions about the possible dependence of IL-17-producing T-cell development on CARD9. However, CARD9 is an adaptor that acts downstream from various receptors, including Dectin-1, Dectin-2, and MINCLE, which can recognise *C. albicans* (Figure 1) (97). The observed IL-17-producing T-cell deficiency may thus result from defects in the production of cytokines promoting IL-17-producing T-cell development or maintenance upon fungal recognition (98, 99). Isolated CMC with an unclear mode of inheritance was reported in a family bearing the Y238X mutation of the *Dectin1* gene with apparent impairment of IL-17 production (52). However, this variation is too frequent (7% in Europeans and up to 40% in the South Africa San population) to be considered disease-causing in AR, AD or codominance models. Finally, high levels of neutralising autoantibodies directed against IL-17A, IL-17F and/or IL-22 have been found in the plasma of patients suffering from AR APSI, in which CMC is the only major infection (Figure 1) (100–102). Together, these findings strongly suggest that impaired IL-17 immunity may underlie CMC (Figure 1) (5).

## 3. “Isolated” CMC or CMCD

This clinical entity usually begins early in infancy and affects otherwise healthy individuals (1, 2, 4, 5). However, some patients also display mild staphylococcal infections of the skin,

albeit less severe than those observed in AD-HIES patients (32, 33, 61), fungal diseases (e.g. dermatophytosis) (25, 26), recurrent herpes virus disease (59) or autoimmune diseases (e.g. thyroid autoimmunity), albeit less severe than that observed in APS-I patients (2, 22, 27, 35, 38, 45, 54, 56–58). The clinical boundaries of this entity have still not clearly described in a large series of patients. The molecular study of these patients led, in 2011, to the identification of the first three genetic aetiologies of CMCD, providing formal proof that IL-17 cytokines are crucial for mucocutaneous protection against *C. albicans* (103, 104). Complete AR IL-17R deficiency and the abolition of cellular responses to IL-17A and IL-17F homo- and heterodimers were observed in a single child born to consanguineous parents. This child displayed CMC, *S. aureus* skin abscesses and folliculitis (105). Partial AD IL-17F deficiency was discovered in a multiplex kindred displaying CMCD, with impaired cellular responses to IL-17F homo- and heterodimers containing the mutant protein (105). More recently, a patient presenting CMC alone was also reported to have a heterozygous mutation in *IL17F*, which has yet to be characterised (106). In the same year, heterozygous missense gain-of-function (GOF) mutations of *STAT1* were identified in patients displaying CMC, autoimmune manifestations and other mild bacterial or viral diseases, together with intracranial aneurysms or squamous cell carcinoma (56–58). In total, 13 heterozygous missense GOF *STAT1* mutations have since been reported, in 73 patients from 29 kindreds (56–60, 69, 103, 104). IL-17-producing T-cell development is impaired in these patients (56, 60, 69), probably due to enhanced STAT1-dependent cellular responses to IL-17-producing T-cell repressors, such as IFN- $\gamma$ , IL-27 and IFN- $\alpha/\beta$  (107–120), and/or enhanced IL-6-, IL-21- and IL-23- STAT1 responses, which normally activate predominantly STAT3, to induce IL-17 T-cell development (56, 104, 121–123). However, no genetic aetiology has yet been identified for a number of patients with CMCD.

## Conclusion

It is almost 40 years since it was first suggested that CMCD was a PID, but the first three genetic aetiologies of this disease were not identified until last year. These experiments of Nature demonstrate the essential role of IL-17A and IL-17F in protective mucocutaneous immunity to *C. albicans* and, to a lesser extent, *S. aureus* in the nails, skin and oral and genital mucosae. These cytokines appear to be otherwise redundant in host defence against other common pathogens. However, description of the precise clinical features of a larger number of patients with inborn errors of IL-17 immunity is required, to determine the role of these cytokines with a greater degree of certainty. We will need to identify more patients with inborn errors of IL-17RA, IL-17F or GOF mutations in *STAT1* or other as yet unknown genetic disorders affecting IL-17 immunity to draw definitive conclusions concerning the impact of these genetic lesions on susceptibility to infection. Nevertheless, the studies carried out to date have already provided invaluable insight into the role of human IL-17 immunity in host defence *in natura* (124–129). They also suggest that the pathogenesis of CMC in settings other than CMCD, whether in inherited disorders or in acquired immunodeficiencies, such as AIDS, probably involves impaired IL-17 immunity. Finally, these studies have also had important clinical implications, as they have made it possible to offer genetic counselling to families with inherited CMC and have provided a rationale for developing new approaches to the treatment of CMC (e.g. treatment with IL-17, GM-CSF or G-CSF) (130) for families with inherited or acquired CMC, based on an understanding of the pathophysiology of human fungal diseases.

## Acknowledgments

We thank the members of the laboratory for helpful discussions, and Yelena Nemirovskaya, Eric Anderson, Martine Courat and Michele N'Guyen for secretarial assistance. This work was supported by grants from INSERM, University Paris Descartes, National Center for Research Resources and the National Center for Advancing Sciences (NCATS), National Institutes of Health grant number 8UL1TR000043, the ANR (grant number

GENCMCD 11-BSV3-005-01), the TÁMOP 4.2.1./B-09/1/KONV-2010-0007 grant to L. Maróvdi, the St. Giles Foundation, and the Candidoser Association awarded to Jean-Laurent Casanova. Sophie Cypowj is supported by the AXA Research Fund.

## References and recommended reading

1. Kirkpatrick CH. Chronic mucocutaneous candidiasis. *Pediatr Infect Dis J.* 2001; 20(2):197–206. [PubMed: 11224843]
2. Lilic D. New perspectives on the immunology of chronic mucocutaneous candidiasis. *Curr Opin Infect Dis.* 2002; 15(2):143–7. [PubMed: 11964914]
3. Husebye ES, Perheentupa J, Rautemaa R, Kampe O. Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. *J Intern Med.* 2009; 265(5):514–29. [PubMed: 19382991]
4. Eyerich K, Eyerich S, Hiller J, Behrendt H, Traidl-Hoffmann C. Chronic mucocutaneous candidiasis, from bench to bedside. *Eur J Dermatol.* 2010
5. Puel A, Picard C, Cypowj S, Lilic D, Abel L, Casanova JL. Inborn errors of mucocutaneous immunity to *Candida albicans* in humans: a role for IL-17 cytokines? *Curr Opin Immunol.* 2010; 22(4):467–74. Epub 2010/08/03. [PubMed: 20674321]
6. Marodi L, Johnston RB Jr. Invasive *Candida* species disease in infants and children: occurrence, risk factors, management, and innate host defense mechanisms. *Curr Opin Pediatr.* 2007; 19(6):693–7. Epub 2007/11/21. [PubMed: 18025938]
7. de Repentigny L, Lewandowski D, Jolicoeur P. Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. *Clin Microbiol Rev.* 2004; 17(4):729–59. table of contents. [PubMed: 15489345]
8. Antachopoulos C, Walsh TJ, Roilides E. Fungal infections in primary immunodeficiencies. *Eur J Pediatr.* 2007; 166(11):1099–117. [PubMed: 17551753]
9. Pirofski LA, Casadevall A. Rethinking T cell immunity in oropharyngeal candidiasis. *J Exp Med.* 2009; 206(2):269–73. Epub 2009/02/11. [PubMed: 19204107]
- \*\*10. Vinh DC. Insights into human antifungal immunity from primary immunodeficiencies. *The Lancet infectious diseases.* 2011; 11(10):780–92. Epub 2011/10/01. A clear and comprehensive review on human immunity to fungal infections. [PubMed: 21958581]
11. Ramos ESM, Lima CM, Schechtman RC, Trope BM, Carneiro S. Superficial mycoses in immunodepressed patients (AIDS). *Clinics in dermatology.* 2010; 28(2):217–25. Epub 2010/03/30. [PubMed: 20347666]
12. Ochs, HD.; Smith, CIE.; Puck, JM. Inc. OUP. Primary immunodeficiency diseases: A molecular and genetic approach. New York: 2012.
13. Al-Herz W, Bousfiha A, Casanova JL, Chapel H, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. *Front Immunol.* 2011; 2:54. [PubMed: 22566844]
14. Minegishi Y. Hyper-IgE syndrome. *Curr Opin Immunol.* 2009; 21(5):487–92. [PubMed: 19717292]
15. Glocker EO, Hennigs A, Nabavi M, Schaffer AA, Woellner C, Salzer U, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. *N Engl J Med.* 2009; 361(18):1727–35. [PubMed: 19864672]
16. Canales L, Middlemas RO 3rd, Louro JM, South MA. Immunological observations in chronic mucocutaneous candidiasis. *Lancet.* 1969; 2(7620):567–71. [PubMed: 4185535]
17. Wells RS. Chronic oral candidiasis (autosomal recessive inheritance) (three cases). *Proc R Soc Med.* 1970; 63(9):890–1. [PubMed: 5477064]
18. Kirkpatrick CH, Rich RR, Graw RG Jr, Smith TK, Mickenberg I, Rogentine GN. Treatment of chronic mucocutaneous moniliasis by immunologic reconstitution. *Clin Exp Immunol.* 1971; 9(6):733–48. [PubMed: 4945734]
19. Wells RS, Higgs JM, Macdonald A, Valdimarsson H, Holt PJ. Familial chronic muco-cutaneous candidiasis. *J Med Genet.* 1972; 9(3):302–10. [PubMed: 4562433]

20. Williamson DM. Chronic hyperplastic candidiasis and squamous carcinoma. *Br J Dermatol.* 1969; 81(2):125–7. [PubMed: 5767066]
21. Fischer A, Ballet JJ, Griscelli C. Specific inhibition of in vitro *Candida*-induced lymphocyte proliferation by polysaccharidic antigens present in the serum of patients with chronic mucocutaneous candidiasis. *J Clin Invest.* 1978; 62(5):1005–13. [PubMed: 361754]
22. Kirkpatrick CH, Greenberg LE, Chapman SW, Goldstein G, Lewis VM, Twomey JJ. Plasma thymic hormone activity in patients with chronic mucocutaneous candidiasis. *Clin Exp Immunol.* 1978; 34(3):311–7. [PubMed: 743805]
23. Kirkpatrick CH, Windhorst DB. Mucocutaneous candidiasis and thymoma. *Am J Med.* 1979; 66(6):939–45. [PubMed: 377963]
24. Sams WM Jr, Jorizzo JL, Snyderman R, Jegasothy BV, Ward FE, Weiner M, et al. Chronic mucocutaneous candidiasis. Immunologic studies of three generations of a single family. *Am J Med.* 1979; 67(6):948–59. [PubMed: 316285]
25. Hay RJ, Wells RS, Clayton YM, Wingfield HJ. Treatment of chronic mucocutaneous candidosis with ketoconazole: a study of 12 cases. *Rev Infect Dis.* 1980; 2(4):600–5. [PubMed: 6255539]
26. Shama SK, Kirkpatrick CH. Dermatophytosis in patients with chronic mucocutaneous candidiasis. *J Am Acad Dermatol.* 1980; 2(4):285–94. [PubMed: 7364986]
27. Jimenez Alonso J, Torres Serrano F, Jaimez L, Ramos Rolon G, Salas Molina J, Perez Borbujo JJ, et al. Candidiasis granuloma associated to hypothyroidism (author's transl). *Med Clin (Barc).* 1981; 77(5):220–3. Granuloma candidiasico asociado a hipotiroidismo. [PubMed: 7329144]
28. Fischer A, Pichat L, Audinot M, Griscelli C. Defective handling of mannan by monocytes in patients with chronic mucocutaneous candidiasis resulting in a specific cellular unresponsiveness. *Clin Exp Immunol.* 1982; 47(3):653–60. [PubMed: 6211308]
29. Yamazaki M, Yasui K, Kawai H, Miyagawa Y, Komiyama A, Akabane T. A monocyte disorder in siblings with chronic candidiasis. A combined abnormality of monocyte mobility and phagocytosis-killing ability. *Am J Dis Child.* 1984; 138(2):192–6. [PubMed: 6695878]
30. McGurk M, Holmes M. Chronic mucocutaneous candidiasis and oral neoplasia. *J Laryngol Otol.* 1988; 102(7):643–5. [PubMed: 3411226]
31. Leroy D, Domp Martin A, Houtteville JP, Theron J. Aneurysm associated with chronic mucocutaneous candidiasis during long-term therapy with ketoconazole. *Dermatologica.* 1989; 178(1):43–6. [PubMed: 2492956]
32. Herrod HG. Chronic mucocutaneous candidiasis in childhood and complications of non-*Candida* infection: a report of the Pediatric Immunodeficiency Collaborative Study Group. *J Pediatr.* 1990; 116(3):377–82. [PubMed: 2308026]
33. Bentur L, Nisbet-Brown E, Levison H, Roifman CM. Lung disease associated with IgG subclass deficiency in chronic mucocutaneous candidiasis. *J Pediatr.* 1991; 118(1):82–6. [PubMed: 1986107]
34. Germain M, Gourdeau M, Hebert J. Case report: familial chronic mucocutaneous candidiasis complicated by deep candida infection. *Am J Med Sci.* 1994; 307(4):282–3. [PubMed: 8160723]
35. Coleman R, Hay RJ. Chronic mucocutaneous candidosis associated with hypothyroidism: a distinct syndrome? *Br J Dermatol.* 1997; 136(1):24–9. [PubMed: 9039290]
36. Grouhi M, Dalal I, Nisbet-Brown E, Roifman CM. Cerebral vasculitis associated with chronic mucocutaneous candidiasis. *J Pediatr.* 1998; 133(4):571–4. [PubMed: 9787702]
37. Loeys BL, Van Coster RN, Defreyne LR, Leroy JG. Fungal intracranial aneurysm in a child with familial chronic mucocutaneous candidiasis. *Eur J Pediatr.* 1999; 158(8):650–2. [PubMed: 10445344]
38. Atkinson TP, Schaffer AA, Grimbacher B, Schroeder HW Jr, Woellner C, Zerbe CS, et al. An immune defect causing dominant chronic mucocutaneous candidiasis and thyroid disease maps to chromosome 2p in a single family. *Am J Hum Genet.* 2001; 69(4):791–803. [PubMed: 11517424]
39. de Moraes-Vasconcelos D, Orii NM, Romano CC, Iqueoka RY, Duarte AJ. Characterization of the cellular immune function of patients with chronic mucocutaneous candidiasis. *Clin Exp Immunol.* 2001; 123(2):247–53. [PubMed: 11207655]
40. Palma-Carlos AG, Palma-Carlos ML. Chronic mucocutaneous candidiasis revisited. *Allerg Immunol (Paris).* 2001; 33(6):229–32. [PubMed: 11505806]

41. Palma-Carlos AG, Palma-Carlos ML, da Silva SL. Natural killer (NK) cells in mucocutaneous candidiasis. *Allerg Immunol (Paris)*. 2002; 34(6):208–12. [PubMed: 12134644]
42. Zuccarello D, Salpietro DC, Gangemi S, Toscano V, Merlino MV, Briuglia S, et al. Familial chronic nail candidiasis with ICAM-1 deficiency: a new form of chronic mucocutaneous candidiasis. *J Med Genet*. 2002; 39(9):671–5. [PubMed: 12205111]
43. Mangino M, Salpietro DC, Zuccarello D, Gangemi S, Rigoli L, Merlino MV, et al. A gene for familial isolated chronic nail candidiasis maps to chromosome 11p12-q12.1. *Eur J Hum Genet*. 2003; 11(6):433–6. [PubMed: 12774035]
44. Lilic D, Gravenor I, Robson N, Lammas DA, Drysdale P, Calvert JE, et al. Deregulated production of protective cytokines in response to *Candida albicans* infection in patients with chronic mucocutaneous candidiasis. *Infect Immun*. 2003; 71(10):5690–9. [PubMed: 14500490]
45. Myhre AG, Stray-Pedersen A, Spangen S, Eide E, Veimo D, Knappskog PM, et al. Chronic mucocutaneous candidiasis and primary hypothyroidism in two families. *Eur J Pediatr*. 2004; 163(10):604–11. [PubMed: 15290270]
46. Ee HL, Tan HH, Ng SK. Autosomal dominant familial chronic mucocutaneous candidiasis associated with acne rosacea. *Ann Acad Med Singapore*. 2005; 34(9):571–4. [PubMed: 16284681]
47. Liu X, Hua H. Oral manifestation of chronic mucocutaneous candidiasis: seven case reports. *J Oral Pathol Med*. 2007; 36(9):528–32. [PubMed: 17850435]
48. Eyerich K, Foerster S, Rombold S, Seidl HP, Behrendt H, Hofmann H, et al. Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. *J Invest Dermatol*. 2008; 128(11):2640–5. [PubMed: 18615114]
49. Marazzi MG, Bondi E, Giannattasio A, Strozzi M, Savioli C. Intracranial aneurysm associated with chronic mucocutaneous candidiasis. *Eur J Pediatr*. 2008; 167(4):461–3. [PubMed: 17443345]
50. Rosa DD, Pasqualotto AC, Denning DW. Chronic mucocutaneous candidiasis and oesophageal cancer. *Med Mycol*. 2008; 46(1):85–91. [PubMed: 17852718]
51. Ryan KR, Hong M, Arkwright PD, Gennery AR, Costigan C, Dominguez M, et al. Impaired dendritic cell maturation and cytokine production in patients with chronic mucocutaneous candidiasis with or without APECED. *Clin Exp Immunol*. 2008; 154(3):406–14. [PubMed: 19037923]
52. Ferwerda B, Ferwerda G, Plantinga TS, Willment JA, van Spruiel AB, Venselaar H, et al. Human dectin-1 deficiency and mucocutaneous fungal infections. *N Engl J Med*. 2009; 361(18):1760–7. [PubMed: 19864674]
53. Hong M, Ryan KR, Arkwright PD, Gennery AR, Costigan C, Dominguez M, et al. Pattern recognition receptor expression is not impaired in patients with chronic mucocutaneous candidiasis with or without autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. *Clin Exp Immunol*. 2009; 156(1):40–51. [PubMed: 19196253]
54. Koch D, Lilic D, Carmichael AJ. Autosomal dominant chronic mucocutaneous candidiasis and primary hypothyroidism complicated by oesophageal carcinoma. *Clin Exp Dermatol*. 2009; 34(8):e818–20. [PubMed: 19778308]
55. Firinu D, Massidda O, Lorrain MM, Serusi L, Peralta M, Barca MP, et al. Successful treatment of chronic mucocutaneous candidiasis caused by azole-resistant *Candida albicans* with posaconazole. *Clinical & developmental immunology*. 2011; 2011:283239. [PubMed: 21197459]
- \*\*56. Liu L, Okada S, Kong XF, Kreins AY, Cypowyj S, Abhyankar A, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. *J Exp Med*. 2011; 208(8):1635–48. Epub 2011/07/06. The authors describe a new and unexpected genetic etiology of CMCD, with dominant mutations in STAT1 in a series of 47 patients. The authors decipher the mechanism of dominance, by showing that the mutant alleles are gain-of-function mostly through an impaired nuclear dephosphorylation of STAT1. These mutations lead to the impairment of IL-17-producing T-cell development, ultimately leading to CMCD in the patients. [PubMed: 21727188]
- \*57. Smeekens SP, Plantinga TS, van de Veerdonk FL, Heinhuis B, Hoischen A, Joosten LA, et al. STAT1 hyperphosphorylation and defective IL12R/IL23R signaling underlie defective immunity in autosomal dominant chronic mucocutaneous candidiasis. *PLoS one*. 2011; 6(12):e29248. [PubMed: 22195034]

- \*58. van de Veerdonk FL, Plantinga TS, Hoischen A, Smeekens SP, Joosten LA, Gilissen C, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. *N Engl J Med*. 2011; 365(1):54–61. [PubMed: 21714643]
- \*59. Toth B, Mehes L, Tasko S, Szalai Z, Tulassay Z, Cypowij C, et al. Herpes in STAT1 mutation. *The Lancet*. 2012 In press.
- \*60. Takezaki S, Yamada M, Kato M, Park MJ, Maruyama K, Yamazaki Y, et al. Chronic Mucocutaneous Candidiasis Caused by a Gain-of-Function Mutation in the STAT1 DNA-Binding Domain. *J Immunol*. 2012 These papers, ref. 56\*\*, 57\*, 58\*, 59\* and 60\* identified heterozygous *STAT1* mutations associated with AD CMCD in a total of 73 patients from 29 kindreds.
61. Chippo BE, Saulsbury FT, Hsu SH, Hughes WT, Winkelstein JA. Non-candidal infections in children with chronic mucocutaneous candidiasis. *Johns Hopkins Med J*. 1979; 144(6):175–9. [PubMed: 459201]
62. Goldberg LS, Bluestone R, Barnett EV, Landau JW. Studies on lymphocyte and monocyte function in chronic mucocutaneous candidiasis. *Clin Exp Immunol*. 1971; 8(1):37–43. [PubMed: 5099755]
63. Lehner T, Wilton JM, Ivanyi L. Immunodeficiencies in chronic muco-cutaneous candidosis. *Immunology*. 1972; 22(5):775–87. [PubMed: 4336639]
64. Gill FF, Portnoy JM. An unusual combination of immunologic abnormalities in a patient with chronic mucocutaneous candidiasis. *Ann Allergy*. 1989; 63(2):98–100. 47–8. [PubMed: 2669569]
65. Kobrynski LJ, Tanimune L, Kilpatrick L, Campbell DE, Douglas SD. Production of T-helper cell subsets and cytokines by lymphocytes from patients with chronic mucocutaneous candidiasis. *Clin Diagn Lab Immunol*. 1996; 3(6):740–5. [PubMed: 8914768]
66. Lilic D, Calvert JE, Cant AJ, Abinun M, Spickett GP. Chronic mucocutaneous candidiasis. II. Class and subclass of specific antibody responses in vivo and in vitro. *Clin Exp Immunol*. 1996; 105(2):213–9. [PubMed: 8706324]
67. Lilic D, Cant AJ, Abinun M, Calvert JE, Spickett GP. Chronic mucocutaneous candidiasis. I. Altered antigen-stimulated IL-2, IL-4, IL-6 and interferon-gamma (IFN-gamma) production. *Clin Exp Immunol*. 1996; 105(2):205–12. [PubMed: 8706323]
68. Lilic D, Gravenor I. Immunology of chronic mucocutaneous candidiasis. *J Clin Pathol*. 2001; 54(2):81–3. [PubMed: 11215289]
69. Eyerich K, Rombold S, Foerster S, Behrendt H, Hofmann H, Ring J, et al. Altered, but not diminished specific T cell response in chronic mucocutaneous candidiasis patients. *Arch Dermatol Res*. 2007; 299(10):475–81. [PubMed: 17960405]
70. Valdimarsson H, Moss PD, Holt PJ, H OJ. Treatment of chronic mucocutaneous candidiasis with leucocytes from HL-A compatible sibling. *Lancet*. 1972; 1(7748):469–72. [PubMed: 4109818]
71. Kirkpatrick CH, Ottenson EA, Smith TK, Wells SA, Burdick JF. Reconstitution of defective cellular immunity with foetal thymus and dialysable transfer factor. Long-term studies in a patient with chronic mucocutaneous candidiasis. *Clin Exp Immunol*. 1976; 23(3):414–28. [PubMed: 947642]
72. Kirkpatrick CH, Smith TK. The nature of transfer factor and its clinical efficacy in the management of cutaneous disorders. *J Invest Dermatol*. 1976; 67(3):425–30. [PubMed: 965788]
73. Kirkpatrick CH, Alling DW. Treatment of chronic oral candidiasis with clotrimazole troches. A controlled clinical trial. *N Engl J Med*. 1978; 299(22):1201–3. [PubMed: 362197]
74. Littman BH, Rocklin RE, Parkman R, David JR. Transfer factor treatment of chronic mucocutaneous candidiasis: requirement for donor reactivity to candida antigen. *Clin Immunol Immunopathol*. 1978; 9(1):97–110. [PubMed: 618414]
75. Caudy AA, Reddy ST, Chatila T, Atkinson JP, Verbsky JW. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. *J Allergy Clin Immunol*. 2007; 119(2):482–7. Epub 2007/01/02. [PubMed: 17196245]
76. Sharfe N, Dadi HK, Shahar M, Roifman CM. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. *Proc Natl Acad Sci U S A*. 1997; 94(7):3168–71. Epub 1997/04/01. [PubMed: 9096364]



77. Picard C, Casanova JL, Puel A. Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IkappaBalpha deficiency. *Clin Microbiol Rev*. 2011; 24(3):490–7. Epub 2011/07/08. [PubMed: 21734245]
78. Zhang Q, Davis JC, Lamborn IT, Freeman AF, Jing H, Favreau AJ, et al. Combined immunodeficiency associated with DOCK8 mutations. *N Engl J Med*. 2009; 361(21):2046–55. Epub 2009/09/25. [PubMed: 19776401]
79. Su HC, Jing H, Zhang Q. DOCK8 deficiency. *Ann N Y Acad Sci*. 2011; 1246:26–33. Epub 2012/01/13. [PubMed: 22236427]
80. Al Khatib S, Keles S, Garcia-Lloret M, Karakoc-Aydiner E, Reisli I, Artac H, et al. Defects along the T(H)17 differentiation pathway underlie genetically distinct forms of the hyper IgE syndrome. *J Allergy Clin Immunol*. 2009; 124(2):342–8. 8 e1–5. Epub 2009/07/07. [PubMed: 19577286]
81. Su HC. Deducator of cytokinesis 8 (DOCK8) deficiency. *Curr Opin Allergy Clin Immunol*. 2010; 10(6):515–20. Epub 2010/09/25. [PubMed: 20864884]
82. Minegishi Y, Karasuyama H. Hyperimmunoglobulin E syndrome and tyrosine kinase 2 deficiency. *Curr Opin Allergy Clin Immunol*. 2007; 7(6):506–9. [PubMed: 17989526]
83. Morgan NV, Goddard S, Cardno TS, McDonald D, Rahman F, Barge D, et al. Mutation in the TCRalpha subunit constant gene (TRAC) leads to a human immunodeficiency disorder characterized by a lack of TCRalphabeta+ T cells. *J Clin Invest*. 2011; 121(2):695–702. Epub 2011/01/06. [PubMed: 21206088]
84. Feske S, Picard C, Fischer A. Immunodeficiency due to mutations in ORAI1 and STIM1. *Clin Immunol*. 2010; 135(2):169–82. Epub 2010/03/02. [PubMed: 20189884]
85. Abdollahpour H, Appaswamy G, Kotlarz D, Diestelhorst J, Beier R, Schaffer AA, et al. The phenotype of human STK4 deficiency. *Blood*. 2012; 119(15):3450–7. Epub 2012/02/02. [PubMed: 22294732]
86. Hambleton S, Salem S, Bustamante J, Bigley V, Boisson-Dupuis S, Azevedo J, et al. IRF8 mutations and human dendritic-cell immunodeficiency. *N Engl J Med*. 2011; 365(2):127–38. Epub 2011/04/29. [PubMed: 21524210]
87. Report of an IUIS Scientific Committee. International Union of Immunological Societies. Primary immunodeficiency diseases. *Clin Exp Immunol*. 1999; 118 (Suppl 1):1–28.
88. Paulson ML, Freeman AF, Holland SM. Hyper IgE syndrome: an update on clinical aspects and the role of signal transducer and activator of transcription 3. *Curr Opin Allergy Clin Immunol*. 2008; 8(6):527–33. Epub 2008/11/04. [PubMed: 18978467]
89. Ma CS, Chew GY, Simpson N, Priyadarshi A, Wong M, Grimbacher B, et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. *J Exp Med*. 2008; 205(7):1551–7. [PubMed: 18591410]
90. Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. *Nature*. 2007; 448(7157):1058–62. [PubMed: 17676033]
91. de Beaucoudrey L, Puel A, Filipe-Santos O, Cobat A, Ghandil P, Chrabieh M, et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. *J Exp Med*. 2008; 205(7):1543–50. Epub 2008/07/02. [PubMed: 18591412]
92. Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. *Nature*. 2008; 452(7188):773–6. [PubMed: 18337720]
93. Renner ED, Rylaarsdam S, Anover-Sombke S, Rack AL, Reichenbach J, Carey JC, et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. *J Allergy Clin Immunol*. 2008; 122(1):181–7. Epub 2008/07/08. [PubMed: 18602572]
94. Hirahara K, Ghoreschi K, Laurence A, Yang XP, Kanno Y, O’Shea JJ. Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. *Cytokine & growth factor reviews*. 2010; 21(6):425–34. Epub 2010/11/19. [PubMed: 21084214]
95. de Beaucoudrey L, Samarina A, Bustamante J, Cobat A, Boisson-Dupuis S, Feinberg J, et al. Revisiting human IL-12Rbeta1 deficiency: a survey of 141 patients from 30 countries. *Medicine (Baltimore)*. 2010; 89(6):381–402. Epub 2010/11/09. [PubMed: 21057261]

96. Filipe-Santos O, Bustamante J, Chappier A, Vogt G, de Beaucoudrey L, Feinberg J, et al. Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. *Seminars in immunology*. 2006; 18(6):347–61. Epub 2006/09/26. [PubMed: 16997570]
97. Drummond RA, Saijo S, Iwakura Y, Brown GD. The role of Syk/CARD9 coupled C-type lectins in antifungal immunity. *Eur J Immunol*. 2011; 41(2):276–81. Epub 2011/01/27. [PubMed: 21267996]
98. LeibundGut-Landmann S, Gross O, Robinson MJ, Osorio F, Slack EC, Tsoni SV, et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. *Nat Immunol*. 2007; 8(6):630–8. [PubMed: 17450144]
99. Robinson MJ, Osorio F, Rosas M, Freitas RP, Schweighoffer E, Gross O, et al. Dectin-2 is a Syk-coupled pattern recognition receptor crucial for Th17 responses to fungal infection. *J Exp Med*. 2009; 206(9):2037–51. [PubMed: 19703985]
100. Kisand K, Boe Wolff AS, Podkrajsek KT, Tserel L, Link M, Kisand KV, et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. *J Exp Med*. 2010; 207(2):299–308. [PubMed: 20123959]
101. Puel A, Doffinger R, Natividad A, Chrabieh M, Barcenas-Morales G, Picard C, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. *J Exp Med*. 2010; 207(2):291–7. Epub 2010/02/04. [PubMed: 20123958]
- \*102. Kisand K, Lilic D, Casanova JL, Peterson P, Meager A, Willcox N. Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients: clinical and pathogenetic implications. *Eur J Immunol*. 2011; 41(6):1517–27. Epub 2011/05/17. An interesting review on the cellular cause of CMC in patients with APS-I syndrome or thymoma. The presence of autoantibodies against IL-17A, IL-17F and/or IL-22 in these patients highlights the specific role of these cytokines in protection against CMC in humans. [PubMed: 21574164]
- \*103. Cypowyj S, Picard C, Casanova JL, Puel A. Immunity to infection in IL-17-deficient mice and humans. *European Journal of Immunology*. 2012 In press. A comprehensive review on the role of IL-17 immunity in infections in mice and humans.
- \*104. Boisson-Dupuis S, Kong XF, Okada S, Cypowyj S, Puel A, Abel L, et al. Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes. *Curr Opin Immunol*. 2012 Epub 2012/06/02. A comprehensive review on the diversity of immunological and infectious phenotypes associated with distinct alleles of *STAT1* in humans.
- \*\*105. Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. *Science*. 2011; 332(6025): 65–8. Epub 2011/02/26. In this paper, the authors identify first two genetic etiologies of CMCD: AR IL-17RA and AD IL-17F deficiencies, thereby demonstrating an essential role of human IL-17A and/or IL-17F in mucocutaneous immunity to *C. albicans in natura*. [PubMed: 21350122]
- \*106. Bader O, Weig MS, Gross U, Schon MP, Mempel M, Buhl T. Photo quiz. A 32-year-old man with ulcerative mucositis, skin lesions, and nail dystrophy. Chronic mucocutaneous candidiasis by multidrug-resistant *Candida albicans*. *Clin Infect Dis*. 2012; 54(7):972–1035. 6. Epub 2012/03/10. In this paper, the authors report a patient with CMCD and IL-17F deficiency. [PubMed: 22403094]
107. Yoshimura T, Takeda A, Hamano S, Miyazaki Y, Kinjyo I, Ishibashi T, et al. Two-sided roles of IL-27: induction of Th1 differentiation on naive CD4+ T cells versus suppression of proinflammatory cytokine production including IL-23-induced IL-17 on activated CD4+ T cells partially through STAT3-dependent mechanism. *J Immunol*. 2006; 177(8):5377–85. Epub 2006/10/04. [PubMed: 17015723]
108. Villarino AV, Gallo E, Abbas AK. STAT1-activating cytokines limit Th17 responses through both T-bet-dependent and -independent mechanisms. *J Immunol*. 2010; 185(11):6461–71. Epub 2010/10/27. [PubMed: 20974984]
109. Tanaka K, Ichiyama K, Hashimoto M, Yoshida H, Takimoto T, Takaesu G, et al. Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads. *J Immunol*. 2008; 180(6): 3746–56. Epub 2008/03/07. [PubMed: 18322180]

110. Stumhofer JS, Laurence A, Wilson EH, Huang E, Tato CM, Johnson LM, et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. *Nat Immunol.* 2006; 7(9):937–45. Epub 2006/08/15. [PubMed: 16906166]
111. Ramgolam VS, Sha Y, Jin J, Zhang X, Markovic-Plese S. IFN-beta inhibits human Th17 cell differentiation. *J Immunol.* 2009; 183(8):5418–27. Epub 2009/09/29. [PubMed: 19783688]
112. Liu H, Rohowsky-Kochan C. Interleukin-27-mediated suppression of human Th17 cells is associated with activation of STAT1 and suppressor of cytokine signaling protein 1. *Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research.* 2011; 31(5):459–69. Epub 2011/01/18.
113. Guzzo C, Che Mat NF, Gee K. Interleukin-27 induces a STAT1/3- and NF-kappaB-dependent proinflammatory cytokine profile in human monocytes. *J Biol Chem.* 2010; 285(32):24404–11. Epub 2010/06/04. [PubMed: 20519510]
114. Feng G, Gao W, Strom TB, Oukka M, Francis RS, Wood KJ, et al. Exogenous IFN-gamma ex vivo shapes the alloreactive T-cell repertoire by inhibition of Th17 responses and generation of functional Foxp3+ regulatory T cells. *Eur J Immunol.* 2008; 38(9):2512–27. Epub 2008/09/16. [PubMed: 18792404]
115. El-behi M, Ciric B, Yu S, Zhang GX, Fitzgerald DC, Rostami A. Differential effect of IL-27 on developing versus committed Th17 cells. *J Immunol.* 2009; 183(8):4957–67. Epub 2009/09/30. [PubMed: 19786534]
116. Diveu C, McGeachy MJ, Boniface K, Stumhofer JS, Sathe M, Joyce-Shaikh B, et al. IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. *J Immunol.* 2009; 182(9):5748–56. Epub 2009/04/22. [PubMed: 19380822]
117. Crabe S, Guay-Giroux A, Tormo AJ, Duluc D, Lissilaa R, Guilhot F, et al. The IL-27 p28 subunit binds cytokine-like factor 1 to form a cytokine regulating NK and T cell activities requiring IL-6R for signaling. *J Immunol.* 2009; 183(12):7692–702. Epub 2009/11/26. [PubMed: 19933857]
118. Chen M, Chen G, Nie H, Zhang X, Niu X, Zang YC, et al. Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS. *Eur J Immunol.* 2009; 39(9):2525–36. Epub 2009/08/12. [PubMed: 19670379]
119. Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, Lucas S, et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. *Nat Immunol.* 2006; 7(9):929–36. Epub 2006/08/15. [PubMed: 16906167]
120. Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. *Nature medicine.* 2007; 13(6):711–8. Epub 2007/05/15.
121. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. *Nature.* 2006; 441(7090):235–8. Epub 2006/05/02. [PubMed: 16648838]
122. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. *Annu Rev Immunol.* 2008; 26:57–79. Epub 2007/10/24. [PubMed: 17953510]
123. Kishimoto T. Interleukin-6: from basic science to medicine—40 years in immunology. *Annu Rev Immunol.* 2005; 23:1–21. Epub 2005/03/18. [PubMed: 15771564]
124. Casanova JL, Abel L. The human model: a genetic dissection of immunity to infection in natural conditions. *Nat Rev Immunol.* 2004; 4(1):55–66. [PubMed: 14704768]
125. Casanova JL, Abel L. Inborn errors of immunity to infection: the rule rather than the exception. *J Exp Med.* 2005; 202(2):197–201. Epub 2005/07/20. [PubMed: 16027233]
126. Casanova JL, Abel L. Primary immunodeficiencies: a field in its infancy. *Science.* 2007; 317(5838):617–9. Epub 2007/08/04. [PubMed: 17673650]
127. Quintana-Murci L, Alcais A, Abel L, Casanova JL. Immunology in natura: clinical, epidemiological and evolutionary genetics of infectious diseases. *Nat Immunol.* 2007; 8(11):1165–71. Epub 2007/10/24. [PubMed: 17952041]

128. Alcais A, Abel L, Casanova JL. Human genetics of infectious diseases: between proof of principle and paradigm. *J Clin Invest*. 2009; 119(9):2506–14. Epub 2009/09/05. [PubMed: 19729848]
129. Alcais A, Quintana-Murci L, Thaler DS, Schurr E, Abel L, Casanova JL. Life-threatening infectious diseases of childhood: single-gene inborn errors of immunity? *Ann N Y Acad Sci*. 2010; 1214:18–33. Epub 2010/11/26. [PubMed: 21091717]
130. Shahar E, Kriboy N, Pollack S. White cell enhancement in the treatment of severe candidosis. *Lancet*. 1995; 346(8980):974–5. Epub 1995/10/07. [PubMed: 7564766]

\$watermark-text

\$watermark-text

\$watermark-text


### Key points

- This article provides an overview on the recent molecular dissection of various primary immunodeficiencies with chronic mucocutaneous candidiasis (CMC) and of isolated CMC (CMCD).
- Altogether these studies have demonstrated the essential role played by human IL-17-mediated immunity in mucocutaneous protection against *C. albicans* and to a lesser extent *against S. aureus in natura*.
- The further genetic and immunological dissection of the pathogenesis of CMCD should delineate the function of various genes controlling IL-17 immunity, of genes only remotely involved in the IL-17 circuit, of genes not previously connected with IL-17, and even of genes governing circuits unrelated to IL-17.

\$watermark-text

\$watermark-text

\$watermark-text



**Figure 1. Inborn errors of IL-17 immunity underlie chronic mucocutaneous candidiasis**  
 Schematic representation of IL-17 mediated immunity with the cooperation between cells recognizing *C. albicans* (phagocytes and epithelial cells) and IL-17 cytokine producing cells (T and innate lymphocytes). Upon *C. albicans* recognition by PRRs (pathogen recognition receptors), including Dectin-1, Dectin-2, or Mincle), the adaptor molecule CARD9 mediates the induction of pro-inflammatory cytokines by myeloid or epithelial cells, such as IL-1β, IL-6 and IL-23. Upon binding to their receptors expressed on T and innate lymphocytes, pro-inflammatory cytokines, such as IL-6 or IL-23, activate T lymphocytes via the transcription factor STAT3 resulting in their differentiation into IL-17-producing T cells. Patients with AR CARD9 deficiency (pink), AD STAT3 deficiency (pink), or AR AIRE deficiency (not represented here) with high levels of neutralizing autoantibodies against IL-17A, IL-17F and/or IL-22 (pink), suffer from syndromic CMC and display impaired IL-17 mediated immunity. Patients with AR IL-17RA or AD IL-17F deficiency and impaired IL-17 response or function, respectively, or with AD STAT1 gain-of-function and impaired development of IL-17 producing T cells suffer from CMCD (in blue).